Andere Sprachen Sage Therapeutics, Inc.

Aktien

A117WF

US78667J1088

SAGE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.04.2024			% 5 Tage	% 1. Jan.
12.57 ^USD	-19.58%		-23.59%	-41.99%

17.04.	SAGE THERAPEUTICS, INC. : BofA Securities senkt Bewertung auf Verkaufen	ZM
17.04.	Gewinnfokus beflügelt börsengehandelte Fonds, Aktienfutures vor dem Glockenschlag am Mittwoch	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Top Midday Decliners	17.04.
Sector Update: Health Care Stocks Advance Premarket Wednesday	17.04.
Sector Update: Health Care	17.04.
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	17.04.
Top Premarket Decliners	17.04.
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint	17.04.
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease	17.04.
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease	17.04.
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024	11.04.
Sage Therapeutics : Announces Dr. Steve Paul to Retire from Board of Directors	26.03.
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board	26.03.
Sage Therapeutics to Present at Upcoming March Investor Conferences	28.02.
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	14.02.
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines	14.02.
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.02.
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M	14.02.
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress	14.02.
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.02.
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024	31.01.
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC	24.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sage Therapeutics, Inc.

Aktien

A117WF

US78667J1088

SAGE

Andere Sprachen

Filter